Genmab — December 2012
-
og Japan vil også drive salget
-
Arzerra har blockbuster potentiale!
-
ikke kun i cancer
-
men også RA og MS
-
om et halvtår det vigtige 1st line forsøg
-
så ruller det eller i 2014
-
maintenance forsøg i 2014 kommer til at betyde mest for omsætningen
-
we believe that the market will grow substantially
-
for arzerra
-
næste nøgne: Daratumumab
-
market for MM vil gro til 9 milliarder dollar
-
det kan bruges som monoterapi
-
Potentiale i dlbcl, fl, mante cell m.fl
-
Nu janssen aftalen
-
deal value potentielt over 1,1 billion dollar
-
fuld fundet og finansiering
-
10 nye studier. og mange fase 3 som janssen initierer
-
cd38 sygdomme bliver fokus
-
nu skal vi lære om Hybrid Business Model
-
profitabilitet in the near future
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind